Plasma Cell Neoplasms
C90WHO Vol. 11 (2024)
Haematolymphoid System
BREAKTHROUGH★ 9.0MedPage Today — Hematology/Oncology
2026-08-13
FDA grants accelerated approval to iberdomide, the first CELMoD, combined with daratumumab and dexamethasone in multiple myeloma
On 13 August 2026 the FDA granted ACCELERATED approval to iberdomide (Zenbexus), the first cereblon E3 ligase modulator (CELMoD), in COMBINATION with daratumumab and hyaluronidase-fihj and dexamethasone — not as monotherapy — for adults with multiple myeloma who have received at least one prior line…
Read the full story →★ 8.0Nature Reviews Clinical Oncology
2026-07-31
Phase 3 MonumenTAL-3: talquetamab plus daratumumab extends progression-free survival in relapsed or refractory multiple myeloma (HR 0.28)
In the randomized phase 3 MonumenTAL-3 trial (864 patients with relapsed or refractory multiple myeloma after at least one prior line, 287 per arm), the GPRC5D-directed bispecific antibody talquetamab — combined with daratumumab and pomalidomide or with daratumumab alone — outperformed daratumumab-p…
Read the full story →